

**Market review**

This has been the worst first half of a year for developed market equities in over 50 years. To make matters worse, there has been no hiding place: government bonds and cash, usually safe havens, have been hit by higher interest rates and rising inflation. Central banks have struggled to deal with an inflationary environment, even as they have brought to an end the long era of “easy money” that has been in place since the Global Financial Crisis. It seems the adage rings true: one crisis leads to another.

For Quality Growth investors, this has resulted in an extremely tricky period, to say the least. The threat of higher interest rates has stalked markets, leading to a significant de-rating of growth stocks – businesses for whom future earnings are vulnerable to higher interest rates. Consumers have faced a significant increase to the cost of living and recessionary fears have heightened.

Although some may have anticipated a marked underperformance of SmallCap versus LargeCap (as is historically typical during periods of market stress), on a global basis, SmallCap has held up relatively well. On a more localised basis, however, the underperformance of the asset class has been far more pronounced: in the UK, SmallCap has underperformed LargeCap by 19% so far this year, while on the Continent it has underperformed by 11%. This, however, is explained not so much by investors’ aversion to smaller companies, but by the make-up of index constituents. In both the UK and Europe, the best performing sector has been Energy, an area of the market dominated by LargeCap names.

**Portfolio**

During the quarter, the NAV of the Trust declined by 20%, an underperformance of 4% relative to the MSCI Europe SmallCap (ex UK) Index. As recessionary fears increased in June, there were signs that Quality was returning to favour, with the NAV outperforming by 1% on a relative basis.

**The strongest contribution** during the quarter came from **Medistim**, the provider of medical devices for improving the quality of heart bypass surgeries, which performed well following continued strong growth in the US. **Chr Hansen**, the Danish supplier of cultures, enzymes and probiotics, gained after reporting strong volume growth across segments. **SimCorp**, the system provider for asset managers, traded up following solid quarterly results and some contract win announcements.

**The weakest contribution** came from **MIPS**, the Swedish manufacturer of a brain protecting helmet insert, which declined on continuing concerns on consumer spending in an inflationary environment, despite increased 2027 sales guidance. **Qt Group**, the leading provider of tools to help developers design and build software applications, weakened after sluggish Q1 growth, although guidance for the full year remains unchanged. **Thule**, the manufacturer of sports and outdoor goods, continued its decline as consumer discretionary spending suffered given rising inflation.

## **Outlook**

While the outlook remains uncertain, the significant decline in equity prices has shifted the risk / reward balance. Equities have significantly de-rated, particularly those in the Quality Growth part of the market. Even if, as seems likely, developed markets enter recessionary territory, selling stocks now and buying them back cheaper at a later date is a game fraught with risk. It is also worth noting that while Value has significantly outperformed Growth so far this year, Value based indices have still posted negative returns.

We believe that the strong outperformance of Value versus Growth may now be behind us. In an uncertain economic environment, the Quality companies that we favour – those that are highly profitable, with sound fundamentals, plenty of cash on their balance sheets and good management teams – remain attractive for long-term investors. We thank you all for your continued support during this difficult six months and look forward to meeting with you again in the coming weeks and months.

---

*The views expressed in this article are those of the author at the date of publication and not necessarily those of Montanaro Asset Management Ltd. The information contained in this document is intended for the use of professional and institutional investors only. It is for background purposes only, is not to be relied upon by any recipient, and is subject to material updating, revision and amendment and no representation or warranty, express or implied, is made, and no liability whatsoever is accepted in relation thereto. This memorandum does not constitute investment advice, offer, invitation, solicitation, or recommendation to issue, acquire, sell or arrange any transaction in any securities. References to the outlook for markets are intended simply to help investors with their thinking about*

*markets and the multiple possible outcomes. Investors should always consult their advisers before investing. The information and opinions contained in this article are subject to change without notice.*